ATE433454T1 - Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors - Google Patents

Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Info

Publication number
ATE433454T1
ATE433454T1 AT05854388T AT05854388T ATE433454T1 AT E433454 T1 ATE433454 T1 AT E433454T1 AT 05854388 T AT05854388 T AT 05854388T AT 05854388 T AT05854388 T AT 05854388T AT E433454 T1 ATE433454 T1 AT E433454T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
halo
Prior art date
Application number
AT05854388T
Other languages
English (en)
Inventor
Martin Clasby
Samuel Chackalamannil
Bernard Neustadt
Xiaobang Gao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE433454T1 publication Critical patent/ATE433454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05854388T 2004-12-21 2005-12-19 Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors ATE433454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63802804P 2004-12-21 2004-12-21
PCT/US2005/045658 WO2006068954A2 (en) 2004-12-21 2005-12-19 PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE433454T1 true ATE433454T1 (de) 2009-06-15

Family

ID=36602229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854388T ATE433454T1 (de) 2004-12-21 2005-12-19 Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Country Status (11)

Country Link
US (1) US7741318B2 (de)
EP (1) EP1836205B1 (de)
JP (1) JP2008524330A (de)
CN (1) CN101119998A (de)
AT (1) ATE433454T1 (de)
CA (1) CA2591125A1 (de)
DE (1) DE602005014891D1 (de)
ES (1) ES2327145T3 (de)
HK (1) HK1108882A1 (de)
MX (1) MX2007007604A (de)
WO (1) WO2006068954A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ES2685837T3 (es) * 2006-08-28 2018-10-11 Merck Sharp & Dohme Corp. Proceso y productos intermedios para la síntesis de derivados de (3-alquil-5-piperidin-1-il-3,3a-dihidropirazolo[1,5-a]pirimidin-7-il)-amino
CN102056925A (zh) * 2008-04-07 2011-05-11 Irm责任有限公司 作为激酶抑制剂的化合物和组合物
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2210891A1 (de) * 2009-01-26 2010-07-28 Domain Therapeutics Neue Adenosin-Rezeptorliganden und Verwendungen davon
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
CN101906105B (zh) * 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
US8835442B2 (en) 2009-11-18 2014-09-16 Council Of Scientific & Industrial Research 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2H-thiazolo [4,5-di pyrimidin-6-yl—and process for preparation thereof
ES2540867T3 (es) * 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
US8354420B2 (en) * 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
RU2014120180A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP6660182B2 (ja) * 2013-03-13 2020-03-11 ジェネンテック， インコーポレイテッド ピラゾロ化合物及びその使用
CN103626776B (zh) * 2013-12-05 2017-02-15 北京师范大学 吡唑并[1,5‑a]嘧啶氮芥衍生物及其制备方法和肿瘤治疗应用
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
CN112996790B (zh) 2018-10-30 2023-11-03 克洛诺斯生物公司 用于调节cdk9活性的化合物、组合物和方法
JP7241871B2 (ja) 2018-11-30 2023-03-17 メルク・シャープ・アンド・ドーム・エルエルシー アデノシン受容体拮抗薬としての９－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
CN112921405B (zh) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 一种合成On-DNA吡唑并[1，5-a]嘧啶化合物的方法
TW202245774A (zh) * 2021-02-05 2022-12-01 大陸商上海齊魯製藥研究中心有限公司 嘧啶或吡啶並雜環類腺苷受體抑制劑及其製備方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
EP0976753B1 (de) 1997-03-24 2004-01-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-DERIVATE
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
CN1377355A (zh) * 1999-09-30 2002-10-30 纽罗杰有限公司 氨基取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
EP1534712B1 (de) * 2002-09-04 2007-05-16 Schering Corporation Pyrazolo[1,5-a]pyrimidine als hemmstoffe cyclin-abhängiger kinasen
KR20050115252A (ko) * 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
EP1608652A1 (de) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidinverbindungen und deren verwendung in der medizin
EP1618108A2 (de) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Als a2a-adenosinrezeptorantagonisten geeignete triazolo[1,5-a]pyrimidine und pyrazolo[1,5-a]pyrimidine

Also Published As

Publication number Publication date
HK1108882A1 (en) 2008-05-23
US7741318B2 (en) 2010-06-22
JP2008524330A (ja) 2008-07-10
WO2006068954A3 (en) 2006-12-07
WO2006068954A2 (en) 2006-06-29
ES2327145T3 (es) 2009-10-26
MX2007007604A (es) 2007-08-02
EP1836205B1 (de) 2009-06-10
DE602005014891D1 (de) 2009-07-23
CA2591125A1 (en) 2006-06-29
US20060135526A1 (en) 2006-06-22
CN101119998A (zh) 2008-02-06
EP1836205A2 (de) 2007-09-26

Similar Documents

Publication Publication Date Title
ATE433454T1 (de) Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
ATE466860T1 (de) Cgrp-rezeptorantagonisten
TW200505903A (en) CGRP receptor antagonists
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ATE503755T1 (de) Cgrp-rezeptorantagonisten
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
DE602006011434D1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
ATE466853T1 (de) Cgrp-rezeptorantagonisten
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE346067T1 (de) Carbolinderivate
ATE507880T1 (de) Cgrp-rezeptorantagonisten
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
MXPA05010651A (es) Compuestos de pirazol.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE384708T1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
SE0303090D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties